Improving outcomes for men with advanced prostate cancer through innovative clinical trials and biomarker development.

Project Details


Prostate cancer (PC) is a common disease and the median survival advantage from novel androgen receptor targeted agents for men with castration resistant disease is measured in months and is not cumulative due to underlying cross-resistance. My research program aims to understand the biology of aggressive forms of PC, define new immune and molecular targets and undertake novel biomarker driven clinical trials that will co-develop new combinations and biomarkers for optimal patient selection.

Effective start/end date1/01/10 → …


  • United States-Israel Binational Science Foundation (BSF)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.